SI2542257T1 - Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Google Patents

Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) Download PDF

Info

Publication number
SI2542257T1
SI2542257T1 SI201131308T SI201131308T SI2542257T1 SI 2542257 T1 SI2542257 T1 SI 2542257T1 SI 201131308 T SI201131308 T SI 201131308T SI 201131308 T SI201131308 T SI 201131308T SI 2542257 T1 SI2542257 T1 SI 2542257T1
Authority
SI
Slovenia
Prior art keywords
tfpi
seq
monoclonal antibodies
residues
sequence
Prior art date
Application number
SI201131308T
Other languages
English (en)
Slovenian (sl)
Inventor
Peter Scholz
Zhuozhi Wang
Junliang Pan
Joanna Grudzinska
Christian Votsmeier
Jan Tebbe
Jorg Birkenfeld
Nina Wobst
Simone Bruckner
Susanne Steinig
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2542257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SI2542257T1 publication Critical patent/SI2542257T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Filtering Materials (AREA)
SI201131308T 2010-03-01 2011-03-01 Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) SI2542257T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01
EP11751244.2A EP2542257B1 (en) 2010-03-01 2011-03-01 Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PCT/US2011/026766 WO2011109452A1 (en) 2010-03-01 2011-03-01 Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI)

Publications (1)

Publication Number Publication Date
SI2542257T1 true SI2542257T1 (en) 2018-01-31

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131308T SI2542257T1 (en) 2010-03-01 2011-03-01 Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
SI201131830T SI3345615T1 (sl) 2010-03-01 2011-03-01 Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201131830T SI3345615T1 (sl) 2010-03-01 2011-03-01 Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)

Country Status (37)

Country Link
US (3) USRE47150E1 (enExample)
EP (2) EP2542257B1 (enExample)
JP (4) JP6025570B2 (enExample)
KR (4) KR101807894B1 (enExample)
CN (5) CN105001335B (enExample)
AU (1) AU2011223710B2 (enExample)
BR (1) BR112012022258A2 (enExample)
CA (3) CA2791685C (enExample)
CL (2) CL2012002415A1 (enExample)
CO (1) CO6620068A2 (enExample)
CR (1) CR20120453A (enExample)
CU (1) CU23982B1 (enExample)
CY (2) CY1119410T1 (enExample)
DK (2) DK2542257T3 (enExample)
DO (1) DOP2012000239A (enExample)
EA (2) EA032189B9 (enExample)
EC (2) ECSP12012134A (enExample)
ES (2) ES2765418T3 (enExample)
GT (1) GT201200252A (enExample)
HK (2) HK1232232A1 (enExample)
HR (2) HRP20171472T1 (enExample)
HU (2) HUE036655T2 (enExample)
IL (3) IL221551B (enExample)
LT (2) LT2542257T (enExample)
ME (2) ME03578B (enExample)
MX (2) MX2012010198A (enExample)
MY (1) MY174760A (enExample)
NZ (2) NZ702494A (enExample)
PE (1) PE20160538A1 (enExample)
PH (4) PH12012501742A1 (enExample)
PL (2) PL3345615T3 (enExample)
PT (2) PT2542257T (enExample)
RS (2) RS59830B1 (enExample)
SG (3) SG183443A1 (enExample)
SI (2) SI2542257T1 (enExample)
SM (1) SMT201700454T1 (enExample)
WO (1) WO2011109452A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101745394B1 (ko) * 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
SG183443A1 (en) * 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
CA2831907C (en) * 2011-04-01 2020-03-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
RU2014143639A (ru) 2012-03-30 2016-05-27 Байер Хелскеа Ллк Регулируемые протеазой антитела
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2970498A4 (en) * 2013-03-15 2016-11-23 Bayer Healthcare Llc PRODUCT ANTIBODIES DIRECTED AGAINST THE INHIBITOR OF THE PATHWAY OF TISSUE FACTOR
CN105452298B (zh) * 2013-03-15 2021-08-31 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
WO2016137108A1 (en) * 2015-02-25 2016-09-01 Mogam Biotechnology Institute Novel antibody binding to tfpi and composition comprising the same
PE20240142A1 (es) 2015-08-19 2024-02-01 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN113645995A (zh) * 2018-10-11 2021-11-12 辉瑞公司 Tfpi拮抗剂的剂量方案
KR102692277B1 (ko) * 2019-03-11 2024-08-05 현대자동차주식회사 상용 전기차용 모터 마운트
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
CZ296649B6 (cs) 1993-02-23 2006-05-17 Genentech, Inc. Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
EP0876140B1 (de) 1996-01-25 2003-10-15 Schering Aktiengesellschaft Verbesserte kontrastmittenlösungen für die intravasale anwendung
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
ES2513043T3 (es) 1997-03-26 2014-10-24 Imperial Innovations Limited Proteína de fusión anticoagulante anclada a membrana de la célula
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1062236A4 (en) 1998-03-12 2005-03-23 Human Genome Sciences Inc 31 HUMAN SECRETED PROTEINS
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
JP4683810B2 (ja) 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤
EP1272211B1 (en) 2000-04-07 2007-06-06 Signal Coordinating Therapy, Inc. Methods and compositions for treating neoplasms
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
EP2275449B1 (en) 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US20040038878A1 (en) 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
WO2002013860A1 (en) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
EP1329224A4 (en) 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
EP1379549A2 (fr) 2001-02-07 2004-01-14 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
AU2002302247A1 (en) 2001-05-21 2002-12-03 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
JP2005523882A (ja) 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2002363253A1 (en) 2001-11-01 2003-05-12 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
WO2003048304A2 (en) 2001-11-29 2003-06-12 Wyeth Holdings Corporation ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFs) ENCODING POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003062375A2 (en) 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
JP2005522999A (ja) 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
WO2003068259A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
AU2003222249A1 (en) 2002-03-04 2003-09-22 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CN1671741A (zh) 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
JP2006502116A (ja) 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
MXPA05005925A (es) 2002-12-02 2006-02-08 Abgenix Inc Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
CA2515583C (en) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1816351A (zh) * 2003-06-27 2006-08-09 艾伯吉尼斯公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
PT1698640E (pt) 2003-10-01 2016-03-31 Kyowa Hakko Kirin Co Ltd Processo para estabilizar um anticorpo e composição sob a forma de solução estabilizada contendo o anticorpo
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US7855274B2 (en) 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
EP2284185A3 (en) 2004-01-09 2011-05-18 Novozymes A/S Bacillus protein inactivation
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
HRP20110320T1 (hr) 2004-05-27 2011-05-31 Crucell Holland B.V. Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
JP2008505192A (ja) 2004-06-14 2008-02-21 メッドイミューン バクシーンズ，インコーポレイティド 生物活性材料の高圧噴霧乾燥
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
HRP20110859T1 (hr) 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EA013118B1 (ru) 2005-01-27 2010-02-26 Новиммун С.А. Антитела против интерферона-гамма и способы их применения
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2595380A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
AU2006219823A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
CN101184775A (zh) 2005-03-04 2008-05-21 伊利诺斯大学理事会 凝血及纤溶级联系统的调控剂
DK1865986T3 (en) 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
TW200714290A (en) 2005-03-08 2007-04-16 Pharmacia & Upjohn Co Llc Anti-M-CSF antibody compositions having reduced levels of endotoxin
AU2005330672B2 (en) 2005-04-18 2011-07-28 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
EP2264162A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
AU2006315026B2 (en) 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
WO2007112054A2 (en) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
AU2007308145A1 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AU2008326348B2 (en) * 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
EP2240156A2 (en) 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
KR20100117120A (ko) 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
AU2009265808B2 (en) 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
MX2011003013A (es) 2008-09-19 2011-04-11 Pfizer Formulacion liquida estable de anticuerpos.
CN104398471A (zh) 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
CN102300876A (zh) 2008-12-22 2011-12-28 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂(tfpi)的抗体
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
WO2010148337A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
PT2473528E (pt) 2009-09-03 2015-03-04 Ablynx NV Formulações estáveis de polipéptidos e seus usos
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
SG183443A1 (en) * 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2673364A1 (en) 2011-02-11 2013-12-18 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CA2831907C (en) 2011-04-01 2020-03-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2013142153A2 (en) 2012-03-22 2013-09-26 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CN105452298B (zh) 2013-03-15 2021-08-31 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
WO2016137108A1 (en) 2015-02-25 2016-09-01 Mogam Biotechnology Institute Novel antibody binding to tfpi and composition comprising the same
PE20240142A1 (es) 2015-08-19 2024-02-01 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos

Also Published As

Publication number Publication date
PH12012501742A1 (en) 2022-03-21
ME03578B (me) 2020-07-20
CU23982B1 (es) 2014-03-26
CN107987166A (zh) 2018-05-04
AU2011223710B2 (en) 2016-04-14
KR101807894B1 (ko) 2017-12-12
US8481030B2 (en) 2013-07-09
HRP20192295T1 (hr) 2020-03-20
EA032189B1 (ru) 2019-04-30
EP3345615A1 (en) 2018-07-11
EA201290849A1 (ru) 2013-05-30
EP3345615B1 (en) 2019-10-16
CN110835373A (zh) 2020-02-25
HK1254947A1 (zh) 2019-08-02
CY1122476T1 (el) 2021-01-27
IL262444A (en) 2018-12-31
IL221551B (en) 2019-08-29
JP2017035100A (ja) 2017-02-16
US20120108796A1 (en) 2012-05-03
KR20190047135A (ko) 2019-05-07
IL262444B (en) 2021-01-31
CY1119410T1 (el) 2018-03-07
KR20130004586A (ko) 2013-01-11
KR101974980B1 (ko) 2019-05-07
RS59830B1 (sr) 2020-02-28
CA3101298A1 (en) 2011-09-09
CN106188301A (zh) 2016-12-07
LT3345615T (lt) 2020-02-10
USRE47150E1 (en) 2018-12-04
LT2542257T (lt) 2017-11-27
HRP20171472T1 (hr) 2017-12-01
JP6684369B2 (ja) 2020-04-22
HUE047173T2 (hu) 2020-04-28
CN102939098B (zh) 2016-08-03
CO6620068A2 (es) 2013-02-15
PE20160538A1 (es) 2016-05-19
MX2012010198A (es) 2012-10-03
PH12018500639A1 (en) 2019-07-29
PH12018500641A1 (en) 2019-07-29
JP6025570B2 (ja) 2016-11-16
IL277391A (en) 2020-11-30
JP6475679B2 (ja) 2019-02-27
CU20120126A7 (es) 2013-01-30
MX354743B (es) 2018-03-16
JP2019089807A (ja) 2019-06-13
EP2542257B1 (en) 2017-07-05
SG10201903166PA (en) 2019-05-30
KR101903931B1 (ko) 2018-10-02
RS56409B1 (sr) 2018-01-31
NZ602115A (en) 2014-12-24
EA032189B9 (ru) 2019-09-30
EP2542257A4 (en) 2013-11-13
MY174760A (en) 2020-05-13
DOP2012000239A (es) 2013-08-15
PT3345615T (pt) 2020-01-17
SMT201700454T1 (it) 2018-01-11
BR112012022258A2 (pt) 2016-10-25
EA201892184A1 (ru) 2019-03-29
US20120329996A1 (en) 2012-12-27
CA2791685C (en) 2019-07-23
CL2012002415A1 (es) 2013-08-23
JP2013520996A (ja) 2013-06-10
ECSP12012134A (es) 2012-09-28
EP2542257A1 (en) 2013-01-09
HUE036655T2 (hu) 2018-07-30
SG10201502587SA (en) 2015-06-29
AU2011223710A1 (en) 2012-09-20
CA2976671A1 (en) 2011-09-09
US9309324B2 (en) 2016-04-12
CA2976671C (en) 2021-01-12
WO2011109452A1 (en) 2011-09-09
KR20170137218A (ko) 2017-12-12
CR20120453A (es) 2013-02-27
JP2020115868A (ja) 2020-08-06
PT2542257T (pt) 2017-10-09
ECSP19025350A (es) 2019-04-30
DK2542257T3 (en) 2017-10-16
GT201200252A (es) 2014-04-03
PL2542257T3 (pl) 2018-01-31
NZ702494A (en) 2016-09-30
KR20180091116A (ko) 2018-08-14
PH12018500640A1 (en) 2019-07-29
CN105001335A (zh) 2015-10-28
SI3345615T1 (sl) 2020-03-31
HK1232232A1 (zh) 2018-01-05
CA2791685A1 (en) 2011-09-09
PL3345615T3 (pl) 2020-07-13
ES2642512T3 (es) 2017-11-16
SG183443A1 (en) 2012-09-27
CL2017003218A1 (es) 2018-06-08
ME02894B (me) 2018-04-20
CN102939098A (zh) 2013-02-20
DK3345615T3 (da) 2020-01-20
ES2765418T3 (es) 2020-06-09
CN105001335B (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
RU2012129735A (ru) Антитела к her3 и их применения
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
AR072039A1 (es) Anticuerpos contra el virus de la hepatitis c
BRPI0606368A2 (pt) anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de hibridoma
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
JP2011173914A5 (enExample)
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
TW200745164A (en) Gene recombination antibodies composition
RU2015150149A (ru) Составы на основе биспецифических антител к il-4/il-13
AR068566A1 (es) Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
PE20141151A1 (es) Proteinas de union al antigeno cd27l
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
AR085624A2 (es) Anticuerpos de p-caderina
EP2543727A4 (en) MODIFIED ANTIBODY COMPOSITION
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
PE20170687A1 (es) Proteinas de enlace a cd127